How much do GLP‑1 medications cost in 2026 - a complete price and coverage guide

Introduction

Cost is the number one barrier to GLP‑1 treatment. Brand-name semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) carry list prices above $1,000 per month, and insurance coverage remains inconsistent. But the pricing landscape is shifting fast in 2026, with new oral options, a landmark Medicare program, and negotiated prices on the horizon. This article breaks down what every major GLP‑1 medication costs, what insurance typically covers, and where the savings are.

What each medication costs without insurance

List prices represent the manufacturer’s stated price before any discounts, coupons, or insurance:

• Ozempic (semaglutide injection, for type 2 diabetes): Approximately $935 per month.
• Wegovy (semaglutide injection, for weight loss): Approximately $1,350 per month.
• Wegovy pill (oral semaglutide, for weight loss): Pricing varies; check with Novo Nordisk’s savings program.
• Mounjaro (tirzepatide injection, for type 2 diabetes): Approximately $1,023 per month.
• Zepbound (tirzepatide injection, for weight loss): Approximately $1,060 per month.
• Foundayo (orforglipron pill, for weight loss): Available through LillyDirect and retail pharmacies; check Lilly’s savings program for current pricing.
• Compounded semaglutide: Starts from approximately $178 per month, though compounded medications are not FDA-approved products and may lack the same quality assurances as brand-name drugs.

These prices change frequently. Always verify current pricing with your pharmacy or the manufacturer’s website.

What insurance typically covers

Coverage depends on why the medication is prescribed:

• Type 2 diabetes: Ozempic and Mounjaro are generally covered by commercial insurance and Medicare Part D when prescribed for diabetes management. Copays typically range from $25 to $100 per month with commercial plans.
• Weight loss: Coverage for Wegovy, Zepbound, and Foundayo varies widely. Many commercial plans now cover at least one weight-loss GLP‑1, but prior authorization is almost always required, and some plans exclude weight-loss medications entirely.
• Cardiovascular risk reduction: Wegovy is covered by some plans, including Medicare Part D, when prescribed for cardiovascular risk reduction in patients with established heart disease and BMI 27 or higher.

The most common reason for coverage denial is the absence of a qualifying diagnosis beyond weight loss alone. Documented comorbidities like hypertension, type 2 diabetes, or sleep apnea significantly improve approval odds.

The Medicare GLP‑1 Bridge program

Starting July 1, 2026, the Medicare GLP‑1 Bridge provides coverage for GLP‑1 weight-loss medications for the first time under a temporary demonstration program. Key details:

• Covered medications: Wegovy (injection and tablet), Zepbound, and Foundayo.
• Cost to patients: A flat $50 copay per 30-day supply, regardless of which Part D benefit phase you are in.
• Manufacturer pricing: Novo Nordisk and Eli Lilly have agreed to provide these medications at a net price of $245 per 30-day supply to the federal government.
• Duration: The program runs from July 1, 2026 through December 31, 2027, after which the BALANCE Model is scheduled to begin.
• Important limitations: The $50 copay does not count toward your Part D deductible or the $2,100 annual out-of-pocket maximum. Low-Income Subsidy cost-sharing reductions do not apply to the Bridge copay. Manufacturer coupons cannot be applied to Bridge claims.

Ozempic and Mounjaro are not part of the Bridge program but remain available through standard Part D for their approved diabetes indications.

How to reduce your costs

• Manufacturer savings programs: Both Novo Nordisk and Eli Lilly offer savings cards that can significantly reduce out-of-pocket costs for commercially insured patients. Check the manufacturer websites for current offers.
• Prior authorization support: Ask your provider to submit detailed documentation including BMI, comorbidities, and treatment history. Tracked data from an app like Shotsy, exported as a PDF, can support this process.
• Appeal denials: If your first authorization is denied, appeal. Many denials are overturned with additional clinical documentation.
• Medicare Bridge enrollment: If you are a Medicare Part D beneficiary, talk to your prescriber about the GLP‑1 Bridge program starting July 2026.
• Negotiate at the pharmacy: Some pharmacies offer competitive cash pricing. Ask about price matching and generic alternatives where available.

Shotsy keeps tracking costs low

Shotsy is free to download with a generous free tier that includes dose logging, weight tracking, side effect logging, nutrition tracking, and PDF export for providers. It does not add to your medication costs, and the documented treatment data can support insurance prior authorization and continued coverage approvals.

Conclusion

GLP‑1 medication costs are real and often frustrating, but the landscape is improving. The Medicare GLP‑1 Bridge, manufacturer savings programs, and the arrival of oral options are all expanding access. Know your coverage options, track your progress to support insurance approvals, and talk to your provider about the most cost-effective path for your situation.